此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Amivantamab 皮下 (SC) 给药治疗晚期实体瘤的研究 (PALOMA)

2026年11月2日 更新者:Janssen Research & Development, LLC

一项开放标签、多中心、剂量递增 1b 期研究,以评估皮下给药阿米万单抗(Amivantamab)的安全性和药代动力学,这是一种用于治疗晚期实体恶性肿瘤的人双特异性 EGFR 和 cMet 抗体

The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

研究概览

研究类型

介入性

注册 (实际的)

158

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5G 2M9
        • University Health Network
    • California
      • West Hollywood、California、美国、90048
        • Cedars Sinai Medical Center
    • Indiana
      • Indianapolis、Indiana、美国、46256
        • Community Health Network
    • New York
      • New York、New York、美国、10016
        • Langone Health at NYC University, NYU School of Medicine
    • Oregon
      • Portland、Oregon、美国、97213
        • Providence Portland Medical Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • Sarah Cannon Research Institute
      • Manchester、英国、M20 4BX
        • The Christie Nhs Foundation Trust
      • Sutton、英国、SM2 5PT
        • Royal Marsden Hospital
      • Cheongju-si、韩国、28644
        • Chungbuk National University Hospital
      • Seongnam-si、韩国、13620
        • Seoul National University Bundang Hospital
      • Seoul、韩国、03722
        • Severance Hospital Yonsei University Health System
      • Seoul、韩国、06351
        • Samsung Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria:

  • Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records.
  • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug
  • A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])

Exclusion criteria:

  • Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded
  • Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels
  • Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible
  • Participant has an active malignancy other than the disease under study requiring treatment
  • Participant has leptomeningeal disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Ami-LC-MD and Ami-LC

Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.

Participants will receive amivantamab admixed with rHuPH20 SC infusion.

Participants will receive amivantamab SC infusion.

实验性的:Part 2: Ami-HC and Ami-HC-CF

Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or SC injection of amivantamab co-formulated with rHuPH20 (Ami-HC-CF).

Participants will receive amivantamab SC infusion.

Participants will receive amivantamab co-formulated with rHuPH20 as SC injection.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
大体时间:Up to Day 29

Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration.

Up to Day 29
Number of Participants with Adverse Event (AE)
大体时间:Up to 4 years 1 month

An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Up to 4 years 1 month
Number of Participants with Dose Limiting Toxicity (DLT)
大体时间:Up to Day 28

Number of participants with DLT will be assessed.

Up to Day 28
Number of Participants with Clinical Laboratory Abnormalities
大体时间:Up to 4 years 1 month

Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed.

Up to 4 years 1 month

次要结果测量

结果测量
措施说明
大体时间
Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies
大体时间:Up to 4 years 1 month

Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed.

Up to 4 years 1 month
Epidermal Growth Factor Receptor (EGFR) Concentrations
大体时间:Up to 4 years 1 month

EGRF concentrations markers will be assessed.

Up to 4 years 1 month
Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers
大体时间:Up to 4 years 1 month

cMET markers will be analyzed.

Up to 4 years 1 month
Overall Response Rate (ORR)
大体时间:Up to 4 years 1 month

ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1.

Up to 4 years 1 month
Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State
大体时间:Up to 4 years 1 month

Maximum amivantamab dosing interval Between time zero to steady state will be assessed.

Up to 4 years 1 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年11月10日

初级完成 (实际的)

2024年7月11日

研究完成 (估计的)

2027年4月1日

研究注册日期

首次提交

2020年10月6日

首先提交符合 QC 标准的

2020年10月22日

首次发布 (实际的)

2020年10月28日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • CR108891
  • 2020-003225-36 (EudraCT编号)
  • 61186372NSC1003 (其他标识符:Janssen Research & Development, LLC)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅